Global RNA-sequencing of a pediatric AML primary sample treated with Tamibarotene or vehicle

The purpose of this study was to assess the global transcriptional changes in a pediatric AML primary sample treated with Tamibarotene. This patient sample has a retinoic acid receptor alpha (RARA) super-enhancer, which is correlated with higher RARA mRNA levels and increased sensitivity to Tamibarotene in vitro and in vivo (Patient-derived xenograft mouse model). There were 4 replicates per treatment condition: Tamibarotene or DMSO (as a control) for the 1 patient sample